App-Quantinova.ai

Comprehensive analyses of long non-coding RNA expression profiles in NSCLC identified AFAP1-AS1 as a prognostic biomarker.

Wenjia Xia - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Association of Rs1008805 polymorphism in the CYP19A1 gene with the prognosis of early breast cancer.

Wang Xiao Jia - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Huge heterogeneity of patient characteristics, treatment patterns, hospital costs exists in non-small cell lung cancer surgeries among different centers of China: A study of 5060 patients based on the Chinese national NSCLC outcome registry.

Jian Zhou - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

The association between body size and susceptibility to breast cancer in Chinese Han women.

Xin Wang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Clinical characteristics and outcome of mucinous breast cancer: A retrospective analysis of 10-year study.

Lei Lei - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Prognositc value of combining cancer metabolism related biomarkers in glioma patients.

Chengcheng Guo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

High-Grade Gliomas

N/A

Implementation of clinical practice guidelines for newly diagnosed GBM patients in China.

Jianmin Zhang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Targeting PIWIL2-like (PL2L) proteins by a monoclonal antibody for immunotherapy of both solid and hematopoietic cancers.

Jian-Xin Gao - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Cervical cancer

N/A

Highly cytotoxic EGFR/CD16A TandAbs to recruit NK-cells to kill EGFR-expressing tumor cells.

Martin Treder - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Anti-EGFRvIII TandAbs recruiting either T- or NK-cells as bispecific therapeutic antibody candidates for the treatment of EGFRvIII+ tumors.

Martin Treder - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

EGFRvIII

Anti-PD-1 to enhance NK-cell cytotoxicity towards CD30+ Hodgkin lymphoma induced by CD30/CD16A TandAb AFM13.

Martin Treder - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hodgkin's Lymphoma

AFM 13

Toxicity profile of cisplatin given at one full dose versus three divided doses for three consecutive days.

Jin Feng Zhang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Cisplatin

A survey on the clinical actionable somatic variations among 1,000 Chinese cancer patients to provide personalized global clinical decision roadmap.

Qiang Xu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

The safety of four cycles of CAPEOX combined with radiotherapy vs. capecitabine combine with radiotherapy for locally advanced rectal cancer: Mid-term analysis of NCT02031939.

Rong-xin Zhang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Capecitabine

Advantages of prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: An open-label, randomized, multicenter phase III study.

Jie Xie - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Recombinant granulocyte colony-stimulating factor

Relation of the BIM deletion polymorphism to intrinsic EGFR-TKI resistance of Chinese patients with EGFR mutant advanced non-small cell lung cancer.

Shuang Xin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Erlotinib hydrochloride

Clinical trial of traditional Chinese medicine (TCM) bionic tiger-bone powder (TB) for the prvention of AI-associatied musculoskeletal symptoms (AMISS).

Wenping Lu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Alora

Use of immunotherapy with patient-specific antigens to select tumor specific T cell receptor (TCR) in cancer patients.

Yanyan Han - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Use of multiple antigens stimulating cellular therapy to treat patients with hepatocellular carcinoma.

Yanyan Han - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

Activation of tumor infiltrating lymphocytes from colorectal cancer and colorectal liver metastasis patients by anti-human PD-1 Antibody BGB-A317 in a 3D spheroid system.

Xiaoran Wu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal liver metastases

Tislelizumab

Filters

24782 Abstracts